RxDoctor Payments Data

Robert Toto, MD

Nephrology · Dallas, TXNPI 1245209725

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $66,217 of the $87,152 with a category attached, or 76.0%. It is spread thinly across 16 manufacturers, the largest accounting for just 18.9%. Among nephrology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$87,152in general payments, 2019–2025

Across 72 payments — averaging $1210.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astrazeneca UK Limited$16K
  • Amgen$9K
  • Vifor Pharma, Inc.$8K
  • Novo Nordisk AS$8K
  • Boehringer Ingelheim International GmbH$7K
  • Alnylam Pharmaceuticals Inc.$7K
  • plus $32K from 10 others
$362,548in research payments, 2019–2025

Across 23 payments — averaging $15,763 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Vertex$346K
  • Akebia Therapeutics Inc$11K
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$4K
  • Amgen$1K

What the payments were for

  • Consulting fees$66,21776%
  • Speaking & faculty fees$10,77512%
  • Travel & lodging$8,69210%
  • Food & beverage$1,4682%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$87,152 in reported general payments places this provider in the 95th percentile of 1,070 nephrology providers in Texas.

See all nephrology providers in Texas

Medicare billing

Part B allowed, 2024
$22,062
Medicare patients
106
Services billed
221

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol28$38,072
KerendiaFinerenone16$17,481
Torsemide23$735
Telmisartan23$718
Losartan Potassium34$377
Carvedilol16$313
Chlorthalidone14$287
Vitamin D2Ergocalciferol (Vitamin D2)11$146
Calcitriol14$112

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$2,163$38,07228 claims
BayerKerendia$12$17,48116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,070 nephrology providers in Texas.

Other nephrology in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →